A 12-week, double-blind, placebo-controlled, randomized, multicenter study of the efficacy of doses of 20 and 60 mg/day istradefylline as treatment for Parkinson's disease in patients with motor response complications on levodopa/carbidopa

Trial Profile

A 12-week, double-blind, placebo-controlled, randomized, multicenter study of the efficacy of doses of 20 and 60 mg/day istradefylline as treatment for Parkinson's disease in patients with motor response complications on levodopa/carbidopa

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Kyowa Pharmaceutical
  • Most Recent Events

    • 03 Jun 2008 Results were published in Neurology.
    • 17 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top